At a Glance
- Company: Asahi Kasei; target: AiCuris Anti-infective Cures
- Location: Tokyo, Japan; Wuppertal, Germany
- Deal value: $920 million all-cash
- Focus area: CMV antivirals, letermovir (Prevymis) successor
- Next steps: Regulatory approvals; pipeline integration
What happened?
Asahi Kasei announced on 26 February 2026 an agreement to acquire AiCuris Anti-infective Cures GmbH for €850 million (~$920M USD) in cash. The deal secures full rights to letermovir, a leading CMV prophylactic, plus AiCuris’ preclinical pipeline targeting cytomegalovirus and other resistant pathogens.
Why does it matter?
CMV infects 60-90% of transplant patients, with few effective therapies amid rising resistance to ganciclovir; AiCuris assets offer next-gen terminase inhibitors with superior resistance profiles. Acquisition expands Asahi Kasei’s pharma footprint beyond dialysis/plasma into high-unmet-need antivirals worth $2B+ annually.
Who’s behind it?
Asahi Kasei Pharma builds infectious disease presence; AiCuris pioneered letermovir (licensed to Merck as Prevymis, $1B+ peak sales). CEOs cited strategic alignment in addressing antimicrobial resistance crisis.
How was it achieved?
AiCuris’ platform targets viral terminase/helicase enzymes for non-nucleoside inhibition; next-gen candidates show 100-fold potency vs wild-type CMV. Deal includes Wuppertal R&D site and 100+ staff for seamless integration.
What’s next?
Closing expected H2 2026 post-antitrust review; phase 1/2 trials accelerate for lead candidates targeting transplant/ congenital CMV. Asahi eyes US/EU filings by 2029.
What are people saying?
Asahi exec: “Bolsters fight against resistant infections.” AiCuris CEO: “Maximises patient impact through global scale.”